Study #2021-0248
A Phase II Study of Venetoclax in Combination with 10-day Oral Decitabine in Relapsed/Refractory Acute Myeloid Leukemia
MD Anderson Study Status
Not Accepting
Treatment Agent
Decitabine and Cedazuridine, Venetoclax
Description
This phase II trial studies the effects of venetoxlax in combination with decitabine and cedazuridine in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as venetoclax and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cedazuridine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving venetoxlax in combination with decitabine and cedazuridine may help to control acute myeloid leukemia.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Biphenotypic Leukemia, Refractory Acute Myeloid Leukemia
Study phase:
Phase II
Physician name:
Abhishek Maiti
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.